ATTYLOID
LIVE

Serial Number

79232535

Owner

Prof. Dr. Dieter Willbold

Filing Date

Sep 1, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ATTYLOID Trademark

Serial Number: 79232535 • Registration: 5870381

ATTYLOID is a trademark filed by Prof. Dr. Dieter Willbold on September 1, 2017. The trademark is classified under Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Prof. Dr. Dieter Willbold (2 trademarks)

Theodor-Heuss-Str. 179

Entity Type: 01

attyloid GmbH

Elsa-Brändström-Str. 34

Entity Type: 98

Trademark Details

Filing Date

September 1, 2017

Registration Date

October 1, 2019

Published for Opposition

July 16, 2019

Cancellation Date

April 17, 2026

Goods & Services

Chemical substances for the production of pharmaceuticals; esters of fatty acids being chemical additives for use in the manufacture of pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industry, namely, chemical additives for use in the manufacture of pharmaceuticals; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical products, namely polypeptides for in vitro research applications; biochemical products, namely, chemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use

Research laboratory analyzers for measuring, testing and analyzing blood and other body fluids; analyzing devices, not for medical purpose, namely pH meters; computer software for the medical sector, namely medical software for controlling and managing patient medical information; computer software for use for systems as support for medical decisions, namely, medical software for processing and displaying images on ultrasound medical imaging machines; diagnostic testing devices for foodstuff, namely, pH meters; diagnostic devices, not for medical purpose namely, diagnostic apparatus for testing food; diagnostic devices for scientific purpose namely, diagnostic apparatus for the detection of pathogens for laboratory or research use; fluorescence analyzers namely, scientific instrument in the nature of fluorescence detector for microscopy; laboratory devices for detecting proteins, namely, immunostaining devices not for medical purpose; lasers, not for medical purpose; lasers for scientific purpose; microscopes for medical purpose; microscopes; particle detector devices for detecting airborne particles; particle classification devices for identifying airborne particles; physical measuring instruments, except for medical purpose namely, instruments for measuring length; physical devices and instruments namely seismometers; physical analyzing devices not for medical purpose, namely pH meters, testing probes, except for medical purpose, namely, probes for testing soil moisture levels

Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluation, namely, services for the evaluation of the therapeutic effects of pharmaceuticals; new product research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testing, analysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services being biological research and analysis; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnology

Medical services; medical services of a health clinic; medical services and health care; medical services of a health farm; health care services of a medical health resort; medical agency services, namely, medical services; medical services for charity purpose; medical services in the field of nephrology; medical services in the field of oncology; medical services in the field of diabetes; medical reporting services, namely, services for drawing up medical reports; medical services, namely, in-vitro insemination; medical services, namely, in vitro fertilization; medical services in the context of house calls; medical services for the treatment of the skin; consulting services in the field of medical care; medical screening-services concerning cardiovascular diseases; provision of medical information concerning medical services; services of medical clinics and health clinics; medical services for the treatment of skin cancer; providing medical information concerning medical services; medical services for people in need in the context of charity; medical services for the treatment of diseases of the human body; medical services for the diagnosis of the condition of the human body; medical services in the field of the treatment of chronic pain; medical services and health care concerning DNA, genetics and genetic tests; medical services concerning the extraction, treatment and processing of bone marrow; medical services concerning the extraction, treatment and processing of stem cells; medical services concerning the extraction, treatment and processing of cord blood; medical services concerning the extraction, treatment and processing of human cells; medical services concerning the extraction, treatment and processing of human blood

Filing History

CANCELLED SECTION 71
Apr 17, 2026 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 1, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 19, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 14, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 27, 2020 FICS
FINAL DISPOSITION PROCESSED
Jan 27, 2020 FIMP
CHANGE OF OWNER RECEIVED FROM IB
Jan 3, 2020 CHLD
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 1, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 1, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 16, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 16, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 26, 2019 NONP
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jun 4, 2019 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
May 22, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 19, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 18, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 18, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 28, 2019 GNRN
NON-FINAL ACTION E-MAILED
Feb 28, 2019 GNRT
NON-FINAL ACTION WRITTEN
Feb 28, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 20, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2018 CRFA
ASSIGNED TO LIE
Dec 20, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 18, 2018 TROA
REFUSAL PROCESSED BY IB
Jul 9, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 18, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jun 18, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 11, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jun 10, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
May 29, 2018 MAFR
ASSIGNED TO EXAMINER
May 25, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 25, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 24, 2018 REPR